MYL:NGS-Mylan N.V.

EQUITY | Drug Manufacturers | Nasdaq Global Select

Last Closing Price

USD 46.51

Change

-0.27 (-0.58)%

Market Cap

USD 24.95B

Volume

6.32M

Yahoo Analyst Target

USD 44.10 (-5.18%)

STA Analyst Target

USD 40.90 (-12.06%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Mylan NV along with its subsidiaries is a pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-01-18 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
WBA Walgreens Boots Alliance Inc.

+0.22 (+0.29%)

USD 75.29B
NBIX Neurocrine Biosciences Inc.

+2.68 (+3.53%)

USD 6.95B
HCM Hutchison China MediTech Limit..

+0.25 (+0.63%)

USD 5.28B
AKRX Akorn Inc.

-0.09 (-0.27%)

USD 4.13B
GWPH GW Pharmaceuticals Plc

-0.45 (-0.34%)

USD 3.35B
HZNP Horizon Pharma plc

+0.22 (+1.47%)

USD 2.49B
IRWD Ironwood Pharmaceuticals Inc.

+0.10 (+0.67%)

USD 2.25B
SUPN Supernus Pharmaceuticals Inc.

-2.95 (-6.34%)

USD 2.23B
AERI Aerie Pharmaceuticals Inc.

+0.50 (+0.87%)

USD 2.13B
MDCO The Medicines Company

-0.34 (-1.34%)

USD 1.82B

ETFs Containing MYL

GNRX VanEck Vectors Generic Dr.. 6.32 % 0.55 %

-0.68 (-0.60%)

USD 3.84M
PPH VanEck Vectors Pharmaceut.. 4.86 % 0.35 %

-0.47 (-0.60%)

USD 0.30B
XPH SPDR S&P Pharmaceuticals 4.75 % 0.35 %

-0.23 (-0.60%)

USD 0.41B
FTXH First Trust Nasdaq Pharma.. 4.49 % 0.60 %

-0.13 (-0.60%)

USD 2.22M
IHE iShares U.S. Pharmaceutic.. 3.95 % 0.44 %

-0.23 (-0.60%)

USD 0.57B
IBLN Direxion iBillionaire Ind.. 3.63 % 0.64 %

+0.08 (+-0.60%)

USD 0.02B
IBB iShares Nasdaq Biotechnol.. 3.11 % 0.47 %

-0.14 (-0.60%)

USD 10.31B
FXH First Trust Health Care A.. 2.30 % 0.62 %

N/A

USD 1.05B
ZUH:CA BMO Equal Weight US Healt.. 2.05 % 0.39 %

+0.02 (+-0.60%)

CAD 0.32B
RYH Guggenheim S&P 500 Equal .. 1.77 % 0.40 %

-0.22 (-0.60%)

USD 0.71B
JKI iShares Morningstar Mid-C.. 1.22 % 0.30 %

-0.70 (-0.60%)

USD 0.44B
FTA First Trust Large Cap Val.. 1.11 % 0.62 %

-0.17 (-0.60%)

USD 1.12B
QQQE Direxion NASDAQ-100 Equal.. 1.05 % 0.35 %

+0.02 (+-0.60%)

USD 0.16B
QQEW First Trust NASDAQ-100 Eq.. 1.03 % 0.60 %

-0.01 (-0.60%)

USD 0.56B
LALT PowerShares Multi-Strateg.. 0.98 % 0.87 %

N/A

USD 4.28M
FAB First Trust Multi Cap Val.. 0.56 % 0.66 %

-0.44 (-0.60%)

USD 0.10B
FEX First Trust Large Cap Cor.. 0.55 % 0.61 %

-0.13 (-0.60%)

USD 1.55B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.93% 71% C- 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.93% 71% C- 83% B
Trailing 12 Months  
Capital Gain 25.06% 65% D 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.06% 65% D 65% D
Trailing 5 Years  
Capital Gain 66.11% 63% D 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.11% 63% D 48% F
Average Annual (5 Year Horizon)  
Capital Gain 7.43% 51% F 48% F
Dividend Return 7.43% 51% F 44% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 32.70% 77% C+ 40% F
Risk Adjusted Return 22.72% 59% F 37% F
Market Capitalization 19.44B 99% A+ 97% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 71.90 7% F 21% F
Price/Book Ratio 1.94 68% D+ 55% F
Price / Cash Flow Ratio 2.97 20% F 43% F
Price/Free Cash Flow Ratio 28.02 10% F 18% F
Management Effectiveness  
Return on Equity 7.11% 76% C 58% F
Return on Invested Capital 4.99% 84% B 54% F
Return on Assets 2.48% 84% B 69% D+
Debt to Equity Ratio 124.25% 24% F 19% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector